GlassScriptPhysician profile
Khalil A Soomro
NPI 1265409296
$3,899.39
in general payments reported to CMS, 2019-2025
18 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $293 · 2021: $1,163 · 2022: $456 · 2023: $725 · 2024: $571 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $872.60 | 2020-2024 | Farxiga, Tezspire, Airsupra |
| Janssen Pharmaceuticals, INC | $711.34 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $338.80 | 2021 | |
| Sunovion Pharmaceuticals INC. | $315.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $249.73 | 2023 | Nucala |
| United Therapeutics Corporation | $189.96 | 2022-2023 | Tyvaso |
| Abbott Laboratories | $144.92 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.20 | 2021 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Veklury |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Cvrx, INC. | $122.44 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2022 | |
| Boston Scientific Corporation | $29.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.13 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $20.57 | 2024 | Monjuvi |
| Puma Biotechnology, INC. | $14.22 | 2024 | |
| Allergan, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Soomro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.